| Literature DB >> 24945412 |
Vincent Chi-Chung Cheng1, Josepha Wai-Ming Tai2, Pui-Hing Chau3, Jonathan Hon-Kwan Chen4, Mei-Kum Yan4, Simon Yung-Chun So4, Kelvin Kai-Wang To5, Jasper Fuk-Woo Chan5, Sally Cheuk-Ying Wong4, Pak-Leung Ho5, Kwok-Yung Yuen5.
Abstract
OBJECTIVE: To control nosocomial transmission of methicillin-resistant Staphylococcus aureus (MRSA) in resource-limited healthcare setting with high endemicity.Entities:
Mesh:
Year: 2014 PMID: 24945412 PMCID: PMC4063951 DOI: 10.1371/journal.pone.0100493
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
The epidemiological characteristics of MRSA in 3 different phases of intervention.
| Phase 1 (1 Jan 2004to 31 Dec 2007) | Phase 2 (1 Jan 2008to 31 Dec 2009) | Phase 3 (1 Jan 2010to 31 Dec 2012) | |
| Total number of MRSA | 1990 | 877 | 1389 |
| Total number of hospital-acquired MRSA | 890 | 315 | 384 |
| Mean number of hospital-acquired MRSA per month | 18.5 | 13.1 | 10.7 |
| Total number of community-acquired MRSA | 1,100 | 562 | 1,005 |
| Mean number of community-acquired MRSA per month | 22.9 | 23.4 | 27.9 |
| Number of MRSA in the major clinical specialties | |||
| Medical unit (hospital- vs community-acquired) | 242 vs 481 | 78 vs 325 | 108 vs 497 |
| Surgical unit (hospital- vs community-acquired) | 327 vs 215 | 114 vs 85 | 146 vs 189 |
| Orthopedic unit (hospital- vs community-acquired) | 91 vs 193 | 42 vs 70 | 55 vs 173 |
| Distribution of MRSA in the major specimen types | |||
| Wound specimens (hospital- vs community-acquired) | 206 vs 383 | 86 vs 209 | 104 vs 392 |
| Respiratory specimens (hospital- vscommunity-acquired) | 361 vs 241 | 125 vs 133 | 188 vs 254 |
| Urine specimens (hospital- vs community-acquired) | 82 vs 166 | 32 vs 74 | 18 vs 97 |
| Sterile body fluid (hospital- vs community-acquired) | 38 vs 78 | 25 vs 57 | 22 vs 145 |
| Blood culture (hospital- vs community-acquired) | 56 vs 91 | 25 vs 40 | 21 vs 47 |
| Total number of admissions | 414,726 | 230,474 | 387,136 |
| Mean number of admissions per month | 8,640 | 9,603 | 10,754 |
| Total number of patient-days | 1,586,799 | 807,159 | 1,295,828 |
| Mean number of patient-days per month | 33,058 | 33,632 | 35,995 |
| Total number of MRSA-positive-days | 48,297 | 16,901 | 30,550 |
| Incidence densities of MRSA | |||
| Hospital-acquired MRSA per 1000 admissions | 2.146 | 1.367 | 0.992 |
| Hospital-acquired MRSA per 1000 patient-days | 0.561 | 0.390 | 0.296 |
| Hospital-acquired MRSA per 1000 MRSA-positive-days | 18.428 | 18.638 | 12.570 |
| Community-acquired MRSA per 1000 admissions | 2.652 | 2.438 | 2.596 |
Note. Phase 1: baseline observation period; phase 2: launch of the first intervention - hand hygiene campaign; phase 3: continuation of phase 2 plus launch of the second intervention - contact precautions.
wound specimens included deep wound, superficial wound, and ulcer swabs.
respiratory specimens included sputum, tracheal aspirates, bronchoalveolar lavage;
urine specimens included mid-stream urine, catheterized urine, suprapubic catheterization, nephrostomy drain urine;
sterile body fluid included pus.
Changes in incidence of MRSA in three different phases of intervention.
| Immediate intervention impact | Pre- intervention trend | Change in trend | ||||||
| Phase 2 vs Phase 1 | Phase 3 vs Phase 2 | Phase 3 vs Phases 1 & 2 | ||||||
| IRR (95% CI) | Percent change(95% CI) | IRR (95% CI) | Percent change(95% CI) | IRR (95% CI) | Percent change(95% CI) | IRR (95% CI) | Percent change(95% CI) | |
| Incidence rate of hospital-acquiredMRSA per 1000 admissions | 0.637 (0.560, 0.724);p<0.001 | −36.3%(−44.0%, −27.6%) | 0.726 (0.625, 0.842);p<0.001 | −27.4%(−37.5%, −15.8%) | NS | NS | NS | NS |
| Incidence rate of hospital-acquiredMRSA per 1000 patient-days | 0.696 (0.612, 0.791);p<0.001 | −30.4%(−38.8%, −20.9%) | 0.759 (0.654, 0.881);p<0.001 | −24.1%(−34.6%, −11.9%) | NS | NS | NS | NS |
| Incidence rate of hospital-acquiredMRSA per 1000 MRSA-positive-days | 0.804 (0.652, 0.990);p = 0.040 | −19.6%(−34.8%, −1.0%) | 0.781 (0.615, 0.990);p = 0.041 | −21.9%(−38.5%, −1.0%) | 1.006 (1.002, 1.011);p = 0.007 | 0.6%(0.2%, 1.1%) | 0.982 (0.971, 0.992);p = 0.001 | −1.8%(−2.9%, −0.8%) |
Note. Phase 1: baseline observation period; phase 2: launch of the first intervention - hand hygiene campaign; phase 3: continuation of phase 2 plus launch of the second intervention - contact precautions;
Insignificant change in trend in Phase 2 vs Phase 1 was found for all models, implying the same slope within Phases 1 and 2;
IRR denotes incidence rate ratio obtained from segmented Poisson regression, and CI denotes confidence intervals;
Percentage change in incidence rate obtained from (IRR−1)×100%; NS, not significant.
Figure 1Incidence rate of hospital-acquired MRSA per 1000 admissions in the three phases of intervention.
Figure 3Incidence rate of hospital-acquired MRSA per 1000 MRSA-positive-days in three different phases of intervention.